KATZ I T , WEINTRAUB R , BEKKER L G , et al . From vaccine nationalism to vaccine equity—finding a path forward [J ] . The New England Journal of Medicine , 2021 , 384 ( 14 ): 1281 - 1283 .

HEINEMAN T C , CONNELLY B L , BOURNE N , et al . Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs [J ] . Journal of Virology , 1995 , 69 ( 12 ): 8109 - 8113 .

CHEN M Y , BUTLER S S , CHEN W T , et al . Physical, chemical, and synthetic virology: reprogramming viruses as controllable nanodevices [J ] . Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology , 2019 , 11 ( 3 ): e1545 .

CAPEDING M R , ALBERTO E R , BOUCKENOOGHE A , et al . Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV-primed children in the Philippines [J ] . The Journal of Infectious Diseases , 2018 , 217 ( 4 ): 567 - 571 .

GARBUTT M , LIEBSCHER R , WAHL-JENSEN V , et al . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses [J ] . Journal of Virology , 2004 , 78 ( 10 ): 5458 - 5465 .

THI NHU THAO T , LABROUSSAA F , EBERT N , et al . Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform [J ] . Nature , 2020 , 582 ( 7813 ): 561 - 565 .

BRAUCHER D R , HENNINGSON J N , LOVING C L , et al . Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs [J ] . Clinical and Vaccine Immunology , 2012 , 19 ( 11 ): 1722 - 1729 .

BETT A J , HADDARA W , PREVEC L , et al . An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3 [J ] . Proceedings of the National Academy of Sciences of the United States of America , 1994 , 91 ( 19 ): 8802 - 8806 .

CORVER J , LENCHES E , SMITH K , et al . Fine mapping of a cis -acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization [J ] . Journal of Virology , 2003 , 77 ( 3 ): 2265 - 2270 .

HILL-BATORSKI L , HATTA Y , MOSER M J , et al . Quadrivalent formulation of intranasal influenza vaccine M2SR (M2-deficient single replication) protects against drifted influenza A and B virus challenge [J ] . Vaccines , 2023 , 11 ( 4 ): 798 .

WONG G , RICHARDSON J S , CUTTS T , et al . Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals [J ] . Antiviral Research , 2015 , 116 : 17 - 19 .

SINZGER C , EBERHARDT K , CAVIGNAC Y , et al . Macrophage cultures are susceptible to lytic productive infection by endothelial-cell-propagated human cytomegalovirus strains and present viral IE1 protein to CD4 + T cells despite late downregulation of MHC class Ⅱ molecules [J ] . Journal of General Virology , 2006 , 87 ( 7 ): 1853 - 1862 .

COOPER D , WRIGHT K J , CALDERON P C , et al . Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice [J ] . Journal of Virology , 2008 , 82 ( 1 ): 207 - 219 .

ZHU F C , LI Y H , GUAN X H , et al . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial [J ] . The Lancet , 2020 , 395 ( 10240 ): 1845 - 1854 .

VAN ZYL-SMIT R N , ESMAIL A , BATEMAN M E , et al . Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial [J ] . American Journal of Respiratory and Critical Care Medicine , 2017 , 195 ( 9 ): 1171 - 1180 .

DE SANTIS O , AUDRAN R , POTHIN E , et al . Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study [J ] . The Lancet Infectious Diseases , 2016 , 16 ( 3 ): 311 - 320 .

PITTMAN P R , HAHN M , LEE H S , et al . Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox [J ] . The New England Journal of Medicine , 2019 , 381 ( 20 ): 1897 - 1908 .

GRAY G E , BEKKER L G , LAHER F , et al . Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults [J ] . The New England Journal of Medicine , 2021 , 384 ( 12 ): 1089 - 1100 .

HUTTNER A , DAYER J A , YERLY S , et al . The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial [J ] . The Lancet Infectious Diseases , 2015 , 15 ( 10 ): 1156 - 1166 .

KIM G N , CHOI J A , WU K Y , et al . A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2 [J ] . PLoS Pathogens , 2021 , 17 ( 12 ): e1010092 .

MA J , YAKASS M B , JANSEN S , et al . Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models [J ] . eBioMedicine , 2022 , 83 : 104240 .

HU P S , CHEN X M , HUANG L H , et al . A highly pathogenic porcine reproductive and respiratory syndrome virus candidate vaccine based on Japanese encephalitis virus replicon system [J ] . PeerJ , 2017 , 5 : e3514 .

KAUGARS K , DARDICK J , DE OLIVEIRA A P , et al . A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2021 , 118 ( 34 ): e2110714118 .

SUMIDA S M , TRUITT D M , LEMCKERT A A C , et al . Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein [J ] . The Journal of Immunology , 2005 , 174 ( 11 ): 7179 - 7185 .

WOHLFART C . Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms [J ] . Journal of Virology , 1988 , 62 ( 7 ): 2321 - 2328 .

ROBERTS D M , NANDA A , HAVENGA M J E , et al . Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity [J ] . Nature , 2006 , 441 ( 7090 ): 239 - 243 .

ABE S , OKUDA K , URA T , et al . Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5 [J ] . The Journal of Gene Medicine , 2009 , 11 ( 7 ): 570 - 579 .

URA T , OKUDA K , SHIMADA M . Developments in viral vector-based vaccines [J ] . Vaccines , 2014 , 2 ( 3 ): 624 - 641 .

FUCHS J D , BART P A , FRAHM N , et al . Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals [J ] . Journal of AIDS & Clinical Research , 2015 , 6 ( 5 ): 461 .

WALSH D S , OWIRA V , POLHEMUS M , et al . Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON ® -TB Gold (+) Kenyan adults without evidence of tuberculosis [J ] . Vaccine , 2016 , 34 ( 21 ): 2430 - 2436 .

MILLIGAN I D , GIBANI M M , SEWELL R , et al . Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial [J ] . JAMA , 2016 , 315 ( 15 ): 1610 - 1623 .

GURWITH M , LOCK M , TAYLOR E M , et al . Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study [J ] . The Lancet Infectious Diseases , 2013 , 13 ( 3 ): 238 - 250 .

VORBURGER S A , HUNT K K . Adenoviral gene therapy [J ] . The Oncologist , 2002 , 7 ( 1 ): 46 - 59 .

YANG T C , DAYBALL K , WAN Y H , et al . Detailed analysis of the CD8 + T-cell response following adenovirus vaccination [J ] . Journal of Virology , 2003 , 77 ( 24 ): 13407 - 13411 .

HIWASA K , NAGAYA H , TERAO S J , et al . Improved gene transfer into bladder cancer cells using adenovirus vector containing RGD motif [J ] . Anticancer Research , 2012 , 32 ( 8 ): 3137 - 3140 .

XIN K Q , JOUNAI N , SOMEYA K , et al . Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV [J ] . Gene Therapy , 2005 , 12 ( 24 ): 1769 - 1777 .

FOUGEROUX C , HOLST P . Future prospects for the development of cost-effective adenovirus vaccines [J ] . International Journal of Molecular Sciences , 2017 , 18 ( 4 ): 686 .

DEAL C , PEKOSZ A , KETNER G . Prospects for oral replicating adenovirus-vectored vaccines [J ] . Vaccine , 2013 , 31 ( 32 ): 3236 - 3243 .

CROSBY C M , BARRY M A . Ⅲa deleted adenovirus as a single-cycle genome replicating vector [J ] . Virology , 2014 , 462/463 : 158 - 165 .

CROSBY C M , MATCHETT W E , ANGUIANO-ZARATE S S , et al . Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses [J ] . Journal of Virology , 2017 , 91 ( 2 ): e00720-16 .

CROSBY C M , NEHETE P , SASTRY K J , et al . Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines [J ] . Journal of Virology , 2015 , 89 ( 1 ): 669 - 675 .

ZYGRAICH N , LOBMANN M , PEETERMANS J , et al . Local and systemic response after simultaneous intranasal inoculation of temperature-sensitive mutants of parainfluenza 3, IBR and bovine adenovirus 3 [J ] . Developments in Biological Standardization , 1975 , 28 : 482 - 488 .

CHENG T , SONG Y F , ZHANG Y , et al . A novel oncolytic adenovirus based on simian adenovirus serotype 24 [J ] . Oncotarget , 2017 , 8 ( 16 ): 26871 - 26885 .

FOLEGATTI P M , EWER K J , ALEY P K , et al . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [J ] . The Lancet , 2020 , 396 ( 10249 ): 467 - 478 .

KAUFMANN J K , NETTELBECK D M . Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond [J ] . Trends in Molecular Medicine , 2012 , 18 ( 7 ): 365 - 376 .

KAUFMAN H L , KOHLHAPP F J , ZLOZA A . Oncolytic viruses: a new class of immunotherapy drugs [J ] . Nature Reviews Drug Discovery , 2015 . 14 ( 9 ): 642 - 662 .

LI J X , HOU L H , MENG F Y , et al . Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial [J ] . The Lancet Global Health , 2017 , 5 ( 3 ): e324 - e334 .

ZHU F C , WURIE A H , HOU L H , et al . Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial [J ] . The Lancet , 2017 , 389 ( 10069 ): 621 - 628 .

KENNEDY S B , BOLAY F , KIEH M , et al . Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia [J ] . New England Journal of Medicine , 2017 , 377 ( 15 ): 1438 - 1447 .

MACKETT M , SMITH G L , MOSS B . Vaccinia virus: a selectable eukaryotic cloning and expression vector [J ] . Proceedings of the National Academy of Sciences of the United States of America , 1982 , 79 ( 23 ): 7415 - 7419 .

HOLGADO M P , FALIVENE J , MAETO C , et al . Deletion of A44L, A46R and C12L vaccinia virus genes from the MVA genome improved the vector immunogenicity by modifying the innate immune response generating enhanced and optimized specific T-cell responses [J ] . Viruses , 2016 , 8 ( 5 ): 139 .

VIEIRA GOMES A , SOUZA CARMO T , SILVA CARVALHO L , et al . Comparison of yeasts as hosts for recombinant protein production [J ] . Microorganisms , 2018 , 6 ( 2 ): 38 .

TAO Q Z , ZHANG H B . Cloning and stable maintenance of DNA fragments over 300 kb in Escherichia coli with conventional plasmid-based vectors [J ] . Nucleic Acids Research , 1998 , 26 ( 21 ): 4901 - 4909 .

DAVISON A J , MOSS B . New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins [J ] . Nucleic Acids Research , 1990 , 18 ( 14 ): 4285 .

FALIVENE J , DEL MÉDICO ZAJAC M P , PASCUTTI M F , et al . Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein [J ] . PLoS One , 2012 , 7 ( 2 ): e32220 .

STICKL H , HOCHSTEIN-MINTZEL V , MAYR A , et al . MVA-Stufenimpfung gegen pocken: klinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA [J/OL ] . Deutsche Medizinische Wochenschrift , 1974 , 99 ( 47 ): 2386 - 2392 [ 2023-09-01 ] . https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0028-1108143 https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0028-1108143 .

GOMEZ C E , NAJERA J L , KRUPA M , et al . MVA and NYVAC as vaccines against emergent infectious diseases and cancer [J ] . Current Gene Therapy , 2011 , 11 ( 3 ): 189 - 217 .

DREXLER I , STAIB C , SUTTER G . Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? [J ] . Current Opinion in Biotechnology , 2004 , 15 ( 6 ): 506 - 512 .

ZHU J G , MARTINEZ J , HUANG X P , et al . Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-Β [J ] . Blood , 2007 , 109 ( 2 ): 619 - 625 .

PRICE P J R , TORRES-DOMÍNGUEZ L E , BRANDMÜLLER C , et al . Modified vaccinia virus Ankara: innate immune activation and induction of cellular signalling [J ] . Vaccine , 2013 , 31 ( 39 ): 4231 - 4234 .

JORDAN I , NORTHOFF S , THIELE M , et al . A chemically defined production process for highly attenuated poxviruses [J ] . Biologicals , 2011 , 39 ( 1 ): 50 - 58 .

COONEY E . Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein [J ] . The Lancet , 1991 , 337 ( 8741 ): 567 - 572 .

GÓMEZ C E , NÁJERA J L , PERDIGUERO B , et al . The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens [J ] . Journal of Virology , 2011 , 85 ( 21 ): 11468 - 11478 .

GARCÍA F , BERNALDO DE QUIRÓS J C L , GÓMEZ C E , et al . Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02) [J ] . Vaccine , 2011 , 29 ( 46 ): 8309 - 8316 .

BAKARI M , ABOUD S , NILSSON C , et al . Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania [J ] . Vaccine , 2011 , 29 ( 46 ): 8417 - 8428 .

CAVENAUGH J S , AWI D , MENDY M , et al . Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection [J ] . PLoS One , 2011 , 6 ( 2 ): e14626 .

BERTHOUD T K , HAMILL M , LILLIE P J , et al . Potent CD8 + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1 [J ] . Clinical Infectious Diseases , 2011 , 52 ( 1 ): 1 - 7 .

BEJON P , OGADA E , MWANGI T , et al . Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya [J ] . PLoS One , 2007 , 2 ( 8 ): e707 .

TAMERIS M D , HATHERILL M , LANDRY B S , et al . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial [J ] . The Lancet , 2013 , 381 ( 9871 ): 1021 - 1028 .

TAPIA M D , SOW S O , LYKE K E , et al . Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial [J ] . The Lancet Infectious Diseases , 2016 , 16 ( 1 ): 31 - 42 .

EWER K , RAMPLING T , VENKATRAMAN N , et al . A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA [J ] . The New England Journal of Medicine , 2016 , 374 ( 17 ): 1635 - 1646 .

CHAN W M , RAHMAN M M , MCFADDEN G . Oncolytic myxoma virus: the path to clinic [J ] . Vaccine , 2013 , 31 ( 39 ): 4252 - 4258 .

GILBERT S C . Clinical development of Modified Vaccinia virus Ankara vaccines [J ] . Vaccine , 2013 , 31 ( 39 ): 4241 - 4246 .

ANTOINE G , SCHEIFLINGER F , DORNER F , et al . The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses [J ] . Virology , 1998 , 244 ( 2 ): 365 - 396 .

OVERTON E T , LAWRENCE S J , WAGNER E , et al . Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial [J ] . PLoS One , 2018 , 13 ( 4 ): e0195897 .

COSMA A , NAGARAJ R , BÜHLER S , et al . Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals [J ] . Vaccine , 2003 , 22 ( 1 ): 21 - 29 .

SAMY N , REICHHARDT D , SCHMIDT D , et al . Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase Ⅰ clinical trial [J ] . Vaccine , 2020 , 38 ( 11 ): 2608 - 2619 .

JOHNSON J E , NASAR F , COLEMAN J W , et al . Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates [J ] . Virology , 2007 , 360 ( 1 ): 36 - 49 .

SUN G Y , FANG X K , WU H , et al . Porcine monocyte-derived dendritic cells can be differentially activated by vesicular stomatitis virus and its matrix protein mutants [J ] . Veterinary Microbiology , 2018 , 219 : 30 - 39 .

RAUCH S , JASNY E , SCHMIDT K E , et al . New vaccine technologies to combat outbreak situations [J ] . Frontiers in Immunology , 2018 , 9 : 1963 .

FUCHS J D , FRANK I , ELIZAGA M L , et al . First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090) [J ] . Open Forum Infectious Diseases , 2015 , 2 ( 3 ): ofv082 .

AGNANDJI S T , HUTTNER A , ZINSER M E , et al . Phase 1 trials of rVSV Ebola vaccine in Africa and Europe [J ] . The New England Journal of Medicine , 2016 , 374 ( 17 ): 1647 - 1660 .

WONG G , MENDOZA E J , PLUMMER F A , et al . From bench to almost bedside: the long road to a licensed Ebola virus vaccine [J ] . Expert Opinion on Biological Therapy , 2018 , 18 ( 2 ): 159 - 173 .

ROBERTS A , BUONOCORE L , PRICE R , et al . Attenuated vesicular stomatitis viruses as vaccine vectors [J ] . Journal of Virology , 1999 , 73 ( 5 ): 3723 - 3732 .

EZELLE H J , MARKOVIC D , BARBER G N . Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector [J ] . Journal of Virology , 2002 , 76 ( 23 ): 12325 - 12334 .

KAHN J S , ROBERTS A , WEIBEL C , et al . Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge [J ] . Journal of Virology , 2001 , 75 ( 22 ): 11079 - 11087 .

GEISBERT T W , JONES S , FRITZ E A , et al . Development of a new vaccine for the prevention of Lassa fever [J ] . PLoS Medicine , 2005 , 2 ( 6 ): e183 .

HERD K A , HARVEY T , KHROMYKH A A , et al . Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour [J ] . Virology , 2004 , 319 ( 2 ): 237 - 248 .

THEILER M , SMITH H H . The use of yellow fever virus modified by in vitro cultivation for human immunization [J ] . Reviews in Medical Virology , 2000 , 10 ( 1 ): 3 - 16 .

MONATH T P , SELIGMAN S J , ROBERTSON J S , et al . Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment [J ] . Vaccine , 2015 , 33 ( 1 ): 62 - 72 .

RECKER M , BLYUSS K B , SIMMONS C P , et al . Immunological serotype interactions and their effect on the epidemiological pattern of dengue [J ] . Proceedings of the Royal Society B: Biological Sciences , 2009 , 276 ( 1667 ): 2541 - 2548 .

YUN S I , LEE Y M . Japanese encephalitis: the virus and vaccines [J ] . Human Vaccines & Immunotherapeutics , 2014 , 10 ( 2 ): 263 - 279 .

LI E , GUO J , OH S J , et al . Anterograde transneuronal tracing and genetic control with engineered yellow fever vaccine YFV-17D [J ] . Nature Methods , 2021 , 18 ( 12 ): 1542 - 1551 .

MONATH T P , LIU J , KANESA-THASAN N , et al . A live, attenuated recombinant West Nile virus vaccine [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2006 , 103 ( 17 ): 6694 - 6699 .

XIAO H , HU H R , GUO Y J , et al . Construction and characterization of a synthesized herpes simplex virus H129-Syn-G2 [J ] . Virologica Sinica , 2023 , 38 ( 3 ): 373 - 379 .

KAMIYAMA T , SATO H , TAKAHARA T , et al . Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen [J ] . The Journal of Infectious Diseases , 2000 , 181 ( 3 ): 1158 - 1161 .

KAUR A , SANFORD H B , GARRY D , et al . Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus [J ] . Virology , 2007 , 357 ( 2 ): 199 - 214 .

TAYLOR T J , DIAZ F , COLGROVE R C , et al . Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector [J ] . Virology , 2016 , 496 : 186 - 193 .

CHESNEY J , AWASTHI S , CURTI B , et al . Phase Ⅲb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage ⅢB-ⅣM1c melanoma [J ] . Melanoma Research , 2018 , 28 ( 1 ): 44 - 51 .

TULMAN E R , DELHON G , AFONSO C L , et al . Genome of horsepox virus [J ] . Journal of Virology , 2006 , 80 ( 18 ): 9244 - 9258 .

NOYCE R S , LEDERMAN S , EVANS D H . Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments [J ] . PLoS One , 2018 , 13 ( 1 ): e0188453 .